Project Grant HT94252510710
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$268K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The Defense Health Agency awarded a $522,477 Project Grant to Boston Medical Center Corporation (BMC) under the Military Medical Research and Development program (CFDA 12.420). The funding will support research to define genetic vulnerabilities in pancreatic neuroendocrine tumors that rely on the alternative lengthening of telomeres pathway. This 3-year project grant runs from August 1, 2023 to July 31, 2026. A sub-award of an unspecified amount was provided to the Trustees of Boston...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,180,294 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to enhance precision oncology for underserved breast cancer patients through deep learning-aided histopathology analysis. The 3-year project, running from September 1, 2025 to August 31, 2028, will leverage MGH's expertise in biomedical research, clinical...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award supports research to cotarget the tumor microenvironment and revolutionize antibody-drug conjugate...
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
This federal Project Grant award of $707,438 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research to determine the molecular etiology of and strategies to block pancreatic cancer cachexia. The award was made on July 15, 2024 with a performance period ending on July 14, 2027. The prime awardee is the University of Massachusetts Medical School's Grants and Contracts Administration Division, which will conduct the research at their...
This Project Grant award of $1,270,020.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in developing personalized cancer vaccines targeting tumor heterogeneity and reprogramming the cold tumor micro-environment in kidney cancer. The award period runs from July 1, 2025 to June 30, 2029. MGH, a renowned non-profit academic medical center and a major...
This $381,312.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at the University of Massachusetts Medical School to determine the molecular etiology of and strategies to block pancreatic cancer cachexia. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Massachusetts Medical School is the awardee and will be conducting the research through its Grants and...
This federal Project Grant award of $144,018.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support the Beckman Research Institute of the City of Hope in conducting a telehealth intervention to impact quality of life and pancreatic cancer survivorship. The award period runs from August 1, 2024 to July 31, 2027. The Project Grant aims to develop and evaluate a telehealth-based intervention to improve outcomes for pancreatic...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $771,627 project grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct advanced biomedical research on tuning and strike targeting of glioblastoma. The 24-month award period runs from August 1, 2025 to July 31, 2027. As a leading academic medical center and recipient of significant federal research funding, Massachusetts General Hospital will...